Biodesix (BDSX) Competitors

$14.76 +0.12 (+0.82%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$14.71 -0.05 (-0.34%)

As of 05/14/2026 06:31 PM Eastern

BDSX vs. FLGT, TOI, VMD, AUNA, and SBC

Should you buy Biodesix stock or one of its competitors? MarketBeat compares Biodesix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biodesix include Fulgent Genetics (FLGT), Oncology Institute (TOI), Viemed Healthcare (VMD), Auna (AUNA), and SBC Medical Group (SBC). These companies are all part of the "healthcare" industry.

How does Biodesix compare to Fulgent Genetics?

Biodesix (NASDAQ:BDSX) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

In the previous week, Fulgent Genetics had 4 more articles in the media than Biodesix. MarketBeat recorded 7 mentions for Fulgent Genetics and 3 mentions for Biodesix. Biodesix's average media sentiment score of 0.63 beat Fulgent Genetics' score of 0.58 indicating that Biodesix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Fulgent Genetics has a net margin of -23.04% compared to Biodesix's net margin of -33.26%. Fulgent Genetics' return on equity of -3.24% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

Biodesix has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

21.0% of Biodesix shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 23.2% of Biodesix shares are owned by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biodesix has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	1.69	-$35.26M	-$4.06	N/A
Fulgent Genetics	$322.67M	1.49	-$60.51M	-$2.39	N/A

Biodesix currently has a consensus target price of $31.00, suggesting a potential upside of 110.03%. Fulgent Genetics has a consensus target price of $27.00, suggesting a potential upside of 66.77%. Given Biodesix's stronger consensus rating and higher possible upside, equities analysts clearly believe Biodesix is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Fulgent Genetics beats Biodesix on 9 of the 16 factors compared between the two stocks.

How does Biodesix compare to Oncology Institute?

Biodesix (NASDAQ:BDSX) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

21.0% of Biodesix shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 23.2% of Biodesix shares are held by insiders. Comparatively, 8.5% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Oncology Institute had 3 more articles in the media than Biodesix. MarketBeat recorded 6 mentions for Oncology Institute and 3 mentions for Biodesix. Oncology Institute's average media sentiment score of 0.79 beat Biodesix's score of 0.63 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncology Institute	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biodesix has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Biodesix presently has a consensus target price of $31.00, suggesting a potential upside of 110.03%. Oncology Institute has a consensus target price of $7.00, suggesting a potential upside of 73.27%. Given Biodesix's higher possible upside, analysts clearly believe Biodesix is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Oncology Institute has a net margin of -7.42% compared to Biodesix's net margin of -33.26%. Oncology Institute's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Oncology Institute	-7.42%	N/A	-24.68%

Biodesix has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	1.69	-$35.26M	-$4.06	N/A
Oncology Institute	$502.73M	0.79	-$60.61M	-$0.37	N/A

Summary

Oncology Institute beats Biodesix on 10 of the 16 factors compared between the two stocks.

How does Biodesix compare to Viemed Healthcare?

Biodesix (NASDAQ:BDSX) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

In the previous week, Biodesix had 2 more articles in the media than Viemed Healthcare. MarketBeat recorded 3 mentions for Biodesix and 1 mentions for Viemed Healthcare. Viemed Healthcare's average media sentiment score of 0.94 beat Biodesix's score of 0.63 indicating that Viemed Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodesix	Positive
Viemed Healthcare	Positive

Biodesix has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Viemed Healthcare has a net margin of 5.20% compared to Biodesix's net margin of -33.26%. Viemed Healthcare's return on equity of 10.52% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Viemed Healthcare	5.20%	10.52%	7.60%

Biodesix currently has a consensus target price of $31.00, suggesting a potential upside of 110.03%. Given Biodesix's stronger consensus rating and higher possible upside, equities analysts plainly believe Biodesix is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Viemed Healthcare has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	1.69	-$35.26M	-$4.06	N/A
Viemed Healthcare	$286.57M	1.27	$14.93M	$0.37	25.65

21.0% of Biodesix shares are held by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Comparatively, 20.0% of Viemed Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Viemed Healthcare beats Biodesix on 10 of the 16 factors compared between the two stocks.

How does Biodesix compare to Auna?

Biodesix (NASDAQ:BDSX) and Auna (NYSE:AUNA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

21.0% of Biodesix shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Biodesix had 2 more articles in the media than Auna. MarketBeat recorded 3 mentions for Biodesix and 1 mentions for Auna. Biodesix's average media sentiment score of 0.63 beat Auna's score of 0.02 indicating that Biodesix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Auna	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biodesix has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Auna has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Auna has a net margin of 2.13% compared to Biodesix's net margin of -33.26%. Auna's return on equity of 19.23% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Auna	2.13%	19.23%	4.70%

Auna has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Auna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	1.69	-$35.26M	-$4.06	N/A
Auna	$1.23B	0.30	$27.39M	$0.36	13.90

Biodesix currently has a consensus target price of $31.00, suggesting a potential upside of 110.03%. Auna has a consensus target price of $7.30, suggesting a potential upside of 45.88%. Given Biodesix's stronger consensus rating and higher possible upside, equities analysts plainly believe Biodesix is more favorable than Auna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Auna	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Auna beats Biodesix on 9 of the 17 factors compared between the two stocks.

How does Biodesix compare to SBC Medical Group?

Biodesix (NASDAQ:BDSX) and SBC Medical Group (NASDAQ:SBC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

21.0% of Biodesix shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 23.2% of Biodesix shares are held by insiders. Comparatively, 89.5% of SBC Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, SBC Medical Group had 4 more articles in the media than Biodesix. MarketBeat recorded 7 mentions for SBC Medical Group and 3 mentions for Biodesix. SBC Medical Group's average media sentiment score of 0.92 beat Biodesix's score of 0.63 indicating that SBC Medical Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SBC Medical Group	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biodesix has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

SBC Medical Group has a net margin of 29.37% compared to Biodesix's net margin of -33.26%. SBC Medical Group's return on equity of 20.76% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
SBC Medical Group	29.37%	20.76%	15.67%

SBC Medical Group has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	1.69	-$35.26M	-$4.06	N/A
SBC Medical Group	$173.61M	1.76	$50.99M	$0.49	6.08

Biodesix currently has a consensus target price of $31.00, suggesting a potential upside of 110.03%. SBC Medical Group has a consensus target price of $8.50, suggesting a potential upside of 185.23%. Given SBC Medical Group's stronger consensus rating and higher probable upside, analysts plainly believe SBC Medical Group is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
SBC Medical Group	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

SBC Medical Group beats Biodesix on 15 of the 16 factors compared between the two stocks.

Get Biodesix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDSX vs. The Competition

Export

Metric	Biodesix	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$147.99M	$8.35B	$6.34B	$12.37B
Dividend Yield	N/A	3.03%	2.80%	5.35%
P/E Ratio	-3.64	21.76	20.66	25.63
Price / Sales	1.69	16.95	542.63	76.59
Price / Cash	N/A	81.29	43.26	56.33
Price / Book	16.40	5.65	9.93	6.97
Net Income	-$35.26M	$183.43M	$3.55B	$333.62M
7 Day Performance	-3.66%	0.26%	1.70%	1.09%
1 Month Performance	16.59%	10.62%	0.49%	3.08%
1 Year Performance	235.45%	3.60%	39.41%	35.68%

Biodesix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDSX Biodesix	3.977 of 5 stars	$14.76 +0.8%	$31.00 +110.0%	+235.5%	$147.99M	$88.50M	N/A	220
FLGT Fulgent Genetics	3.0108 of 5 stars	$15.12 +7.0%	$32.00 +111.6%	-17.7%	$420.33M	$322.67M	N/A	1,315	High Trading Volume
TOI Oncology Institute	3.9992 of 5 stars	$4.08 +0.7%	$7.00 +71.6%	+70.5%	$400.30M	$502.73M	N/A	660
VMD Viemed Healthcare	2.0785 of 5 stars	$9.48 -4.9%	N/A	+38.1%	$383.68M	$270.28M	25.62	1,382
AUNA Auna	4.2642 of 5 stars	$4.97 -3.3%	$7.30 +46.8%	-27.7%	$380.43M	$1.23B	13.81	15,254	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDSX) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodesix (BDSX) Competitors

BDSX vs. FLGT, TOI, VMD, AUNA, and SBC

How does Biodesix compare to Fulgent Genetics?

Summary

How does Biodesix compare to Oncology Institute?

Summary

How does Biodesix compare to Viemed Healthcare?

Summary

How does Biodesix compare to Auna?

Summary

How does Biodesix compare to SBC Medical Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodesix (BDSX) Competitors

BDSX vs. FLGT, TOI, VMD, AUNA, and SBC

How does Biodesix compare to Fulgent Genetics?

Does the media prefer BDSX or FLGT?

Is BDSX or FLGT more profitable?

Which has more volatility & risk, BDSX or FLGT?

Do institutionals & insiders have more ownership in BDSX or FLGT?

Which has preferable earnings and valuation, BDSX or FLGT?

Do analysts recommend BDSX or FLGT?

Summary

How does Biodesix compare to Oncology Institute?

Do insiders and institutionals have more ownership in BDSX or TOI?

Does the media favor BDSX or TOI?

Which has more risk and volatility, BDSX or TOI?

Do analysts rate BDSX or TOI?

Is BDSX or TOI more profitable?

Which has higher valuation and earnings, BDSX or TOI?

Summary

How does Biodesix compare to Viemed Healthcare?

Does the media prefer BDSX or VMD?

Which has more risk & volatility, BDSX or VMD?

Is BDSX or VMD more profitable?

Do analysts rate BDSX or VMD?

Which has higher earnings & valuation, BDSX or VMD?

Do institutionals & insiders hold more shares of BDSX or VMD?

Summary

How does Biodesix compare to Auna?

Do institutionals & insiders hold more shares of BDSX or AUNA?

Does the media prefer BDSX or AUNA?

Which has more risk & volatility, BDSX or AUNA?

Is BDSX or AUNA more profitable?

Which has higher earnings & valuation, BDSX or AUNA?

Do analysts rate BDSX or AUNA?

Summary

How does Biodesix compare to SBC Medical Group?

Do insiders and institutionals hold more shares of BDSX or SBC?

Does the media favor BDSX or SBC?

Which has more volatility and risk, BDSX or SBC?

Is BDSX or SBC more profitable?

Which has stronger earnings and valuation, BDSX or SBC?

Do analysts rate BDSX or SBC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools